As such, BRAFi+MEKi therapy resistance not only reinstates tumor cell proliferation and survival, but may simultaneously dampen immune-mediated tumor control through a complex network of tumor-intrinsic transcriptional changes, that could be partly driven by an upregulation of Cyclin D1. The gene discussed is CCND1; the disease is neoplasm.